Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.

Related Articles

Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.

Future Oncol. 2016 May;12(9):1117-24

Authors: Meattini I, Desideri I, Di Cataldo V, Francolini G, De Luca Cardillo C, Scotti V, Loi M, Detti B, Mangoni M, Agresti B, Baldazzi V, Greto D, Casella D, Bernini M, Sanchez LJ, Orzalesi L, Nori J, Fambrini M, Bianchi S, Livi L

Abstract
AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT.
RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%.
CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.

PMID: 26956105 [PubMed - indexed for MEDLINE]

http://ift.tt/2hs59Oc